Antiplatelet therapy with acetylsalicylic acid: Approaches to reducing the frequency of gastrointenstinal adverse reactions


Cite item

Full Text

Abstract

Acetylsalicylic acid (ASA) is highly effective in preventing cardiovascular events, but associated with increased risk for digestive adverse reactions. The paper provides an update on the epidemiology, mechanisms, and risk factors of esophagogastroduodeno- and enteropathies during long-term low-dose ACA therapy. It outlines the key principles of their prevention.

Full Text

Антитромбоцитарная терапия ацетилсалициловой кислотой: подходы к снижению частоты нежелательных явлений со стороны желудочно-кишечного тракта. - Аннотация. Прием ацетилсалициловой кислоты (АСК) высокоэффективен для профилактики сердечно-сосудистых осложнений, но сопряжен с повышением вероятности нежелательных явлений со стороны органов пищеварения. В статье представлены современные данные по эпидемиологии, механизмам развития и факторам риска эзофагогастродуодено- и энтеропатий на фоне длительной терапии низкими дозами АСК. Изложены ключевые принципы их профилактики.
×

About the authors

E V Onuchina

Email: elonu@mail.ru

References

  1. Vonkeman H.E., van de Laar M.A. Nonsteroidal anti-inflammatory drugs: adverse effects and their prevention. Semin Arthritis Rheum 2010; 39 (4): 294-312.
  2. Kawai T., Watanabe M., Yamashina A. Impact of upper gastrointestinal lesions in patients on low-dose aspirin therapy: preliminary study. J Gastroenterol Hepatol 2010; 25 (1): 23-30.
  3. Taha A.S., McCloskey C., Prasad R., Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009; 374 (9684): 119-1125.
  4. Yeomans N., Lanas A., Labenz J. et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 2008; 103 (10): 2465-2473.
  5. Tamura A., Murakami K., Kadota J. Prevalence and independent factors for gastroduodenal ulcers/erosions in asymptomatic patients taking low-dose aspirin and gastroprotective agents: the OITA-GF study. QJM 2011; 104 (2): 133-139.
  6. Yamagata M., Hiraishi H. Prevalence and incidence of NSAID-induced gastrointestinal ulcers and bleeding. Nihon Rinsho 2007; 65 (10): 1749-1753.
  7. Shiotani A., Kamada T. Haruma K. Low-dose aspirin-induced gastrointestinal diseases: past, present, and future. J Gastroenterol 2008; 43 (8): 581-588.
  8. Kawamura N., Ito Y., Sasaki M. et al. Low-dose aspirin-associated upper gastric and duodenal ulcers in Japanese patients with no previous history of peptic ulcers. BMC Res Notes 2013; 6: 455.
  9. Lin K.J., De Caterina R., Rodríguez L.A. Low-dose aspirin and upper gastrointestinal bleeding in primary versus secondary cardiovascular prevention: a population-based, nested case-control study. Circ Cardiovasc Qual Outcomes 2014; 7 (1): 70-77.
  10. Smecuol E., Pinto Sanchez M.I., Suarez A. et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009; 7 (5): 524-529.
  11. Endo H., Sakai E., Higurashi T. et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis 2012; 44 (10): 833-838.
  12. Mizukami K., Murakami K., Abe T. et al. Aspirin-induced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol 2011; 17 (46): 5117-5122.
  13. Casado Arroyo R., Polo-Tomas M., Roncalés M.P. et al. Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart 2012; 98 (9): 718-723.
  14. Hreinsson J.P., Gumundsson S., Kalaitzakis E., Björnsson E.S. Lower gastrointestinal bleeding: incidence, etiology, and outcomes in a population-based setting. Eur J Gastroenterol Hepatol 2013; 25 (1): 37-43.
  15. Mousavi M., Salehimarzijarani B., Dadvar Z. et al. Relationship between continuous use of low-dose enteric-coated aspirin and gastrointestinal injuries in patients with gastrointestinal hemorrhage. Turk J Gastroenterol 2013; 24 (2): 93-98.
  16. Takada M., Fujimoto M., Hosomi K. Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin. Int J Clin Pharmacol Ther 2014; 52 (3): 181-191.
  17. Wallace J.L. Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 2008; 88 (4): 1547-1565.
  18. Arakawa T., Watanabe T., Tanigawa T. et al. Small intestinal injury caused by NSAIDs/aspirin: finding new from old. Curr Med Chem 2012; 19 (1): 77-81.
  19. Cea Soriano L., García Rodríguez L.A. Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. Front Pharmacol 2010; 14: 126.
  20. Lanas A., Bajador E., Serrano P. et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343 (12): 834-839.
  21. Serrano P., Lanas A., Arroyo M.T., Ferreira I.J. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002; 16 (11): 1945-1953.
  22. Feldman M., Cryer B., Mallat D., Go M.F. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial. Am J Gastroenterol 2001; 96 (6): 1751-1757.
  23. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359 (9300): 14-22.
  24. Lanas A., García-Rodríguez L.A., Arroyo M.T. et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007; 102 (3): 507-515.
  25. Bae S.E., Kim S.E., Jung S.A. et al. The effect of aspirin alone or aspirin plus additional antiplatelets therapy on upper gastrointestinal hemorrhage. Korean J Gastroenterol 2011; 57 (4): 213-220.
  26. Shiotani A., Honda K., Murao T. et al. Combination of low-dose aspirin and thienopyridine exacerbates small bowel injury. Scand J Gastroenterol 2011; 46 (3): 281-286.
  27. Takahashi Y., Nishida Y., Nakayama T., Asai S. Comparative effect of clopidogrel and aspirin versus aspirin alone on laboratory parameters: a retrospective, observational, cohort study. Cardiovasc Diabetol 2013; 12 (1): 87.
  28. García Rodríguez L.A., Johansson S., Nagy P., Cea Soriano L. Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care. Thromb Haemost 2014; 111 (1): 131-139.
  29. Abbas A.E., Brodie B., Dixon S. et al. Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 96 (2): 173-176.
  30. Moukarbel G.V., Signorovitch J.E., Pfeffer M.A. et al. Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. Eur Heart J 2009; 30 (18): 2226-2232.
  31. Donnelly M.T., Goddard A.F., Filipowicz B. et al. Low-dose misoprostol for the prevention of low-dose aspirin-induced gastroduodenal injury. Aliment Pharmacol Ther 2000; 14 (5): 529-534.
  32. Goldstein J.L., Huang B., Amer F., Christopoulos N.G. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther 2004; 26 (10): 1637-1643.
  33. Rostom A., Muir K., Dube C. et al. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Healthc Patient Saf 2009; 1: 47-71.
  34. Hardin C.K., Sexton C.R., Peoples J.B. Efficacy of sucralfate in preventing peptic ulceration induced by nonsteroidal anti-inflammatory drugs. Am Surg 1987; 53 (7): 373-376.
  35. Malchow-Møller A., Ranløv P.J. Does sucralfate reduce acetylsalicylic-acid-induced gastric mucosal bleeding? Scand J Gastroenterol 1987; 22 (5): 550-552.
  36. Konturek S.J., Kwiecień N., Obtułwicz W., Oleksy J. Gastroprotection by sucralfate against acetylsalicylic acid in humans. Role of endogenous prostaglandins. Scand J Gastroenterol 1987; 140: 19-22.
  37. Dajani E.Z., Agrawal N.M. Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs. Dig Dis 1995; 1: 48-61.
  38. Konturek S.J., Kwiecień N., Obtułwicz W. et al. Effects of colloidal bismuth subcitrate on aspirin-induced gastric microbleeding, DNA loss, and prostaglandin formation in humans. Scand J Gastroenterol 1988; 23 (7): 861-866.
  39. Chen S.P., Chen J., Wen S.H. Protective effect of colloidal bismuth subcitrate on gastric mucosal lesion induced by aspirin. Zhonghua Nei Ke Za Zhi 1990; 29 (5): 293-295.
  40. Berkowitz J.M., Rogenes P.R., Sharp J.T., Warner C.W. Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med 1987; 147 (12): 2137-2139.
  41. Ng F.H., Tunggal P., Chu W.M. et al. Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. Am J Gastroenterol 2012; 107 (3): 389-396.
  42. Sanuki T., Fujita T., Kutsumi H. et al. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. J Gastroenterol 2012; 47 (11): 1186-1197.
  43. Bhatt D.L., Cryer B.L., Contant C.F. et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363 (20): 1909-1917.
  44. Zairis M.N., Tsiaousis G.Z., Patsourakos N.G. et al. The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol 2010; 26 (2): 54-57.
  45. Brooks J., Warburton R., Beales I.L. Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis 2013; 4 (5): 206-222.
  46. Malfertheiner P., Megraud F., O'Morain C.A. et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 2012; 61 (5): 646-664.
  47. Sugimoto M., Uotani T., Nishino M. et al. Antiplatelet drugs are a risk factor for esophageal mucosal injury. Digestion 2013; 87 (4): 281-289.
  48. Watanabe T., Sugimori S., Kameda N. et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6 (11): 1279-1282.
  49. Shiotani A., Haruma K., Nishi R. et al. Randomized, double-blind, pilot study of geranylgeranylacetone versus placebo in patients taking low-dose enteric-coated aspirin. Low-dose aspirin-induced small bowel damage. Scand J Gastroenterol 2010; 45 (3): 292-298.
  50. Tanigawa T., Watanabe T., Ohkawa F. et al. Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase. J Clin Biochem Nutr 2011; 48 (2): 149-153.
  51. Watari I., Oka S., Tanaka S. et al. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterol 2013; 13: 108.
  52. Leite A.Z., Sipahi A.M., Damião A.O. et al. Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism. Gut 2001; 48 (2): 163-167.
  53. Davies G.R., Wilkie M.E., Rampton D.S. Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci 1993; 38 (3): 417-425.
  54. Bjarnason I., Hayllar J., Smethurst P. et al. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992; 33 (9): 1204-1208.
  55. Uejima M., Kinouchi T., Kataoka K. et al. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol Immunol 1996; 40 (8): 553-560.
  56. Muraki M., Fujiwara Y., Machida H. et al. Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users. Scand J Gastroenterol 2014; 49 (3): 267-273.
  57. Watanabe T., Nishio H., Tanigawa T. et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 2009; 297 (3): 506-513.
  58. Montalto M., Gallo A., Curigliano V. et al. Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther 2010; 32 (2): 209-214.
  59. Endo H., Higurashi T., Hosono K. et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study. J Gastroenterol 2011; 46 (7): 894-905.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies